Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology

Aug 22 2016

• By Jessica Merrill

Related Content

Mylan Turns To Meda In Sweden For Open Door Into Consumer Market

Feb 15 2016

Medivation/Astellas’ <em>Xtandi</em> A Tough Rival For J&J’s <em>Zytiga</em>

Sep 10 2012

Medivation Rejects Sanofi's Latest Bid, But Enters Confidential Negotiations

Jul 06 2016

With Medivation, Pfizer Sees A Chance For More Combinations

Aug 22 2016

Pfizer Buys Anacor With Blockbuster Ambitions For Crisaborole

May 16 2016

Related Companies

Medivation, Inc.

Pfizer Inc.

Sanofi

Astellas Pharma, Inc.

Bristol Myers Squibb Company

Merck & Co., Inc.

Gilead Sciences, Inc.

Allergan plc

Anacor Pharmaceuticals, Inc.

Viatris Inc.

Meda AB

Perrigo Company PLC

Additional Topics

Deals Commercial Cancer BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window